Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Rating of “Hold” by Brokerages

Inspire Medical Systems, Inc. (NYSE:INSP) has earned an average rating of “Hold” from the twenty research firms that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $81.0526.

Several brokerages have recently issued reports on INSP. Wells Fargo & Company lowered their price objective on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 5th. Summit Redstone set a $39.00 price objective on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Piper Sandler downgraded shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $85.00 to $55.00 in a research report on Tuesday, May 5th. Robert W. Baird lowered their price objective on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating for the company in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada downgraded shares of Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a research report on Monday, June 15th.

Institutional Investors Weigh In On Inspire Medical Systems

Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP acquired a new position in Inspire Medical Systems during the fourth quarter worth $203,929,000. Wasatch Advisors LP boosted its holdings in Inspire Medical Systems by 7.2% during the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after purchasing an additional 110,288 shares during the last quarter. William Blair Investment Management LLC boosted its holdings in Inspire Medical Systems by 68.7% during the third quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock worth $96,280,000 after purchasing an additional 528,404 shares during the last quarter. Morgan Stanley boosted its holdings in Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after purchasing an additional 809,121 shares during the last quarter. Finally, Deerfield Management Company L.P. boosted its holdings in Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after purchasing an additional 907,694 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Stock Performance

Shares of NYSE:INSP opened at $45.65 on Tuesday. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03. The company has a market capitalization of $1.32 billion, a PE ratio of 10.17, a PEG ratio of 4.63 and a beta of 0.73. The company has a 50 day moving average price of $45.52 and a two-hundred day moving average price of $65.66.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The company had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The firm’s revenue was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, sell-side analysts forecast that Inspire Medical Systems will post 0.93 earnings per share for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.